glp-1 agonists oral FDA just approved orforglipron (Foundayo), Eli Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest The Next Wave of Obesity

Your metabolism, energy, mental clarity, and skin are all connected

M.LinicI

New strategies for the development of antifungal drugs have gradually become a research hotspot, including the targeting of novel biological pathways, the combination of antifungal drugs, the development of fungal vaccines, the creation of innovative therapeutics (such as small-molecule peptides and nanoparticles), the extraction of active ingredients from traditional Chinese medicine, and the utilization of artificial intelligence in drug design ( Figure 1 ) (Wall and Lopez-Ribot, 2020

Free standard shipping on orders over $300

The discovery or design of native (exenatide) or engineered GLP-1 analogues that escape DPP-4 degradation and have a prolonged half-life, as well as DPP-4 inhibitors, have markedly improved the therapeutic landscape of type 2 diabetes over the last 13 years